Early Drug Development Group

Our preclinical and clinical operation structures rely on an interdisciplinary group of medical oncologists, pharmacologists and molecular biology experts with extensive experience in preclinical studies and clinical trials. We are capable of offering professional services covering all stages of your R&D program, to establish an attractive route to the clinic in a fast, efficient and cost effective manner.
Learn More
Optimize, Innovate, Collaborate
We support medtech and biotech start-ups, pharmaceutical companies, investment fund groups and academic organizations in oncology to foster their R&D programs in a time- and cost-effective manner.
Management and execution of an efficient R&D program in oncology.
Broad capabilities in preclinical, pharmacokinetics and radiopharmacology studies to guide clinical development.
Assistance on preclinical, pharmacological and CMC approaches, regulatory strategies and Phase I clinical trials in oncology.
Advice on the reliability and feasibility of reported preclinical and clinical data.


Our strength relies on an interdisciplinary team of medical oncologists, pharmacologists and molecular biology experts with unparalleled experience in non-clinical and clinical trial studies.


We are interdisciplinary research group of medical oncologists, pharmacologists and molecular biology experts. We have performed several drug development programs with more than 20 companies -ranging from small biotech to the largest pharma companies- for the evaluation of over 20 different leads (at least 8 first-in-man) in oncology, covering both small molecules and monoclonal antibodies.   Over the last years, we have established a long-standing network of trusted partner companies and world-class investigators experienced in early drug development and cancer research in oncology and immunology. This enable us to offer an attractive route to the clinic optimized in terms of time and costs.

Contact Info

  •   1 Place Paul Verlaine 92100. France
  •   e2dg.contact@e2dg.com.
  •   +33 1 83 75 86 32.

Season's Greetings & Happy New Year! From all of us at E2DG

Posted on December 18, 2019.

The Swiss National Science Foundation (SNSF) awards the Tumor Biology and Experimental Therapeutics Group (IOR, Switzerland) headed by Prof. Carlo Catapano; the Department of Chemistry, Center for Life Sciences and Technologies (Bogazici University, Turkey) directed by Prof. Rana Sanyal and Early Drug Development Group (E2DG, France) for the project "Nanoparticle-based delivery and combinatorial therapies for cancer"

To get more information follow this link.

December 12, 2019.

"Accelerating the drug discovery process" Conference 2019, Pisa, Italy.

Our CSO, Dr. Riveiro Maria Eugenia will discuss the last improvements made in drug development with other international experts from academia and pharmaceutical companies. To get more information on this conference follow this link.

Posted on November 11, 2019.

E2DG forms a strategic collaboration with Fusion Antibodies to provide end-to-end service for oncology drug discovery companies.

This deal between Fusion Antibodies & E2DG will allow oncology drug discovery companies to benefit from Fusion Antibodies’ expertise in the discovery and early development of novel and highly developable therapeutic antibodies and from the experience of E2DG in preclinical efficacy and phase I/II oncology clinical trials.

To get more information on this conference follow this link.

More News


We look forward to learning about your specific needs, please contact us.